Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment on the Deep Remission Rate and Its Influencing Factors of Individualized Ustekinumab Therapy in Patients With Crohn's Disease

NCT07600255 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT07600255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07600255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment on the Deep Remission Rate and Its Influencing Factors of Individualized Ustekinumab Therapy in Patients With Crohn's Disease
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Observational
Overall status
Completed
Start date
January 1, 2021
Completion date
January 20, 2026
Enrollment
156 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's diseases